NCT04694365View on ClinicalTrials.gov

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 1, 2021

Primary Completion Date

June 19, 2024

Study Completion Date

June 19, 2024

Conditions
Hepatic ImpairmentHealthy Subjects
Interventions
DRUG

Fluzoparib

A single oral dose of 50 mg Fluzoparib will be administered.

Trial Locations (1)

Unknown

Henan Infectious Diseases Hospital, Zhengzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT04694365 - Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function | Biotech Hunter | Biotech Hunter